Literature DB >> 24472819

Irinotecan-induced immune thrombocytopenia.

Barry C Mirtsching1, James N George, Richard H Aster, Brian R Curtis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24472819      PMCID： PMC4060798          DOI： 10.1097/MAJ.0000000000000243

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN： 0002-9629            Impact factor:   2.378


× No keyword cloud information.
  7 in total

1.  Immune thrombocytopenia induced by fludarabine successfully treated with rituximab.

Authors:  Maria J Fernandez; Inmaculada Llopis; Emilio Pastor; Esperanza Real; Enric Grau
Journal:  Haematologica       Date:  2003-02       Impact factor: 9.941

Review 2.  Oxaliplatin-related thrombocytopenia.

Authors:  D L Jardim; C A Rodrigues; Y A S Novis; V G Rocha; P M Hoff
Journal:  Ann Oncol       Date:  2012-04-25       Impact factor: 32.976

Review 3.  Drug-induced immune thrombocytopenia.

Authors:  Richard H Aster; Daniel W Bougie
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245

4.  Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin.

Authors:  Brian R Curtis; James Kaliszewski; Marisa B Marques; M Wasif Saif; Lisle Nabelle; Jules Blank; Janice G McFarland; Richard H Aster
Journal:  Am J Hematol       Date:  2006-03       Impact factor: 10.047

5.  Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex.

Authors:  B R Curtis; J G McFarland; G G Wu; G P Visentin; R H Aster
Journal:  Blood       Date:  1994-07-01       Impact factor: 22.113

6.  Irinotecan-induced immune thrombocytopenia.

Authors:  L Bozec; P Bierling; P Fromont; F Lévi; P Debat; E Cvitkovic; J L Misset
Journal:  Ann Oncol       Date:  1998-04       Impact factor: 32.976

7.  Immune-mediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: the unresolved issues.

Authors:  Soumen Khatua; Chandrika N Nair; Kanjaksha Ghosh
Journal:  J Pediatr Hematol Oncol       Date:  2004-11       Impact factor: 1.289
  7 in total
  2 in total

1.  Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies.

Authors:  Brian R Curtis; Yen-Michael S Hsu; Nikolai Podoltsev; Jill Lacy; Susanna Curtis; Michael S Samuel; Kristin Zutavern; Robert A DeSimone; Daniel W Bougie; Richard H Aster
Journal:  Blood       Date:  2018-02-12       Impact factor: 22.113

2.  Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy.

Authors:  Eric L Tam; Padma L Draksharam; Jennifer A Park; Gurinder S Sidhu
Journal:  Case Rep Oncol Med       Date:  2019-11-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.